Lexeo Therapeutics, Inc. (LXEO) Income Statement
LXEO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLXEO revenue and net income
LXEO profit margins
LXEO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LXEO quarterly EPS vs estimates
Lexeo Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.33).
LXEO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $654,000 | $1.7M | $518,476 |
| Cost of revenue | $2.1M | $2.0M | $1.8M | $1.1M | $13,405 | $0 |
| Gross profit | −$2.1M | −$2.0M | −$1.8M | $654,000 | $1.7M | $518,476 |
| Research & development | $63.8M | $74.1M | $53.1M | $49.2M | $45.1M | $4.3M |
| Sales, general & admin | $45.5M | $31.7M | $15.4M | $12.0M | $7.2M | $787,499 |
| Total operating expenses | $109.3M | $105.8M | $68.5M | $61.2M | $52.3M | $5.1M |
| Operating income | −$109.3M | −$105.8M | −$68.5M | −$60.5M | −$50.6M | −$4.6M |
| Interest income | $6.1M | $7.6M | $2.9M | $1.3M | $15,000 | — |
| Interest expense | $206,000 | $114,000 | $205,000 | $91,000 | $0 | $147,150 |
| Income before taxes | −$100.0M | −$98.3M | −$66.4M | −$59.3M | −$50.6M | −$5.2M |
| Income taxes | — | — | −$1 | $89,000 | −$155 | $147,150 |
| Net income | −$100.0M | −$98.3M | −$66.4M | −$59.3M | −$50.6M | −$5.2M |
| EBITDA | −$97.7M | −$96.2M | −$64.3M | −$58.0M | −$50.6M | −$4.6M |
| EPS (diluted) | −$2.27 | −$3.08 | −$2.05 | −$2.36 | — | — |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating margin | — | — | — | −9,252.1% | −3,055.9% | −884.9% |
| Net margin | — | — | — | −9,063.8% | −3,055.0% | −993.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.9M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $546,000 | $538,000 | $530,000 | $510,000 | $501,000 | $972,000 | $509,000 | $496,000 | $476,000 | $490,000 | $460,000 |
| Gross profit | — | −$546,000 | −$538,000 | −$530,000 | −$510,000 | −$501,000 | $972,000 | −$509,000 | −$496,000 | −$476,000 | −$490,000 | −$460,000 |
| Research & development | $19.0M | $15.7M | $16.2M | $15.7M | $14.7M | $17.2M | $18.4M | $23.4M | $16.6M | $15.7M | $8.2M | $17.2M |
| Sales, general & admin | $9.0M | $6.6M | $6.9M | $6.0M | $16.0M | $16.6M | $9.0M | $8.1M | $7.0M | $7.5M | $6.8M | $3.0M |
| Total operating expenses | $28.0M | $21.8M | $23.1M | $21.6M | $30.7M | $33.8M | $27.4M | $31.5M | $23.6M | $23.3M | $15.0M | $20.3M |
| Operating income | −$28.0M | −$22.3M | −$23.1M | −$21.6M | −$30.7M | −$33.8M | −$27.4M | −$31.5M | −$23.6M | −$23.3M | −$15.0M | −$20.3M |
| Interest income | $2.2M | $2.2M | $2.2M | $1.5M | $1.3M | $1.2M | $1.5M | $2.1M | $2.3M | $1.7M | $1.1M | $488,000 |
| Interest expense | $14,000 | $17,000 | $25,000 | $82,000 | $59,000 | $40,000 | $30,000 | $35,000 | $35,000 | $37,000 | $50,000 | $52,000 |
| Income before taxes | −$25.9M | −$20.2M | −$20.9M | −$20.3M | −$26.1M | −$32.7M | −$25.9M | −$29.5M | −$21.2M | −$21.7M | −$14.2M | −$20.1M |
| Income taxes | — | — | — | — | — | — | — | — | — | $32,000 | $43,000 | $53,000 |
| Net income | −$25.9M | −$20.2M | −$20.9M | −$20.3M | −$26.1M | −$32.7M | −$25.9M | −$29.5M | −$21.2M | −$21.7M | −$14.2M | −$20.1M |
| EBITDA | −$25.3M | −$19.6M | −$20.4M | −$19.7M | −$25.5M | −$32.1M | −$25.4M | −$28.9M | −$20.7M | −$21.2M | −$13.6M | −$19.6M |
| EPS (diluted) | −$0.30 | −$0.25 | −$0.27 | −$0.33 | −$0.68 | −$0.99 | −$0.78 | −$0.89 | −$0.64 | −$0.77 | −$0.85 | −$1.20 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −1,408.5% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −1,333.5% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LXEO's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LXEO financial results
Lexeo Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $100.0 million. Diluted earnings per share came to −$2.27.
See the LXEO stock overview for the latest quote and news, or the LXEO chart for price history and technical indicators.
LXEO income statement FAQ
Does Lexeo Therapeutics have revenue?
Lexeo Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Lexeo Therapeutics profitable?
No. Lexeo Therapeutics reported a net loss of $100.0 million in fiscal 2025.
How much does Lexeo Therapeutics spend on research and development?
Lexeo Therapeutics spent $63.8 million on research and development in fiscal 2025.
What are Lexeo Therapeutics's earnings per share?
Lexeo Therapeutics earned $-2.27 per diluted share in fiscal 2025, compared with $-3.08 a year earlier.
When will Lexeo Therapeutics report its next earnings?
Lexeo Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens.
When does Lexeo Therapeutics's fiscal year end?
Lexeo Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.